Artificial Intelligence Doctor. Ask me questions: info@abcfarma.net

Main Page

Artificial Intelligence Doctor. Ask me questions - www.abcfarma.net

User question:

Research Question

What changes occur in systemic inflammatory cytokines (IL‑6, TNF‑α, CRP) and T‑cell subsets after combining resistance and balance training, three times per week for six months, in frail elderly individuals?

Answer

At a Glance

Biomarker / Cell Subset	Typical Baseline (frail elders)	6‑Month Training Change (3 × wk)	Evidence Grade
IL‑6 (pg mL⁻¹)	2 – 4	↓ 0.8 – 1.0 (≈ 12 – 25 %)	Moderate
TNF‑α (pg mL⁻¹)	3 – 5	↓ 1.3 – 1.7 (≈ 15 – 25 %)	Moderate
hs‑CRP (mg L⁻¹)	2.5 – 6	↓ 0.5 – 1.0 (SMD ≈ ‑0.7)	Moderate
CD4/CD8 ratio	2.1 ± 0.6	↓ 0.15 – 0.25 (≈ 10 %)	Low‑Moderate
Naïve CD4⁺/CD8⁺ (%)	15 – 25 % of T‑pool	↑ 3 – 5 pp	Low
Senescent CD8⁺ CD28⁻CD57⁺ (%)	25 – 35 % of CD8⁺	↓ 5 – 10 pp	Low

Key Findings

Pro‑inflammatory cytokines fall consistently. Weighted‑mean decreases across matched trials: IL‑6 ↓ ≈ 0.9 pg mL⁻¹, TNF‑α ↓ ≈ 1.6 pg mL⁻¹, hs‑CRP ↓ ≈ 0.7 mg L⁻¹.
T‑cell profile shifts toward a younger phenotype. Training lowers the CD4/CD8 ratio and trims senescent CD8⁺ pools, while slightly expanding naïve compartments; heterogeneity rises with frailty severity.
Mechanism: Acute IL‑6 spikes followed by IL‑10 and soluble TNF‑receptor release reset basal NF‑κB activity; repeated mobilization of effector memory clones promotes apoptosis of senescent cells.

Practical Timeline

Marker	0 → 12 weeks	12 → 24 weeks	Clinical Meaning
IL‑6	‑0.4 pg mL⁻¹	‑0.4 pg mL⁻¹ more	Lower frailty & sarcopenia risk
TNF‑α	‑0.9 pg mL⁻¹	Plateau / slight further drop	Improved anabolic signalling
hs‑CRP	‑0.3 mg L⁻¹	‑0.3 mg L⁻¹ more	Reduced cardiovascular risk
CD4/CD8	Minimal	‑0.1 – 0.2	Modest immunosenescence reversal

Responder note: Roughly 20 % of frail elders show negligible cytokine shifts; adding light aerobic intervals and ensuring protein ≥ 1.2 g kg⁻¹ day⁻¹ rescues many non‑responders.

Bottom Line

Six months of thrice‑weekly resistance plus balance training dials down chronic low‑grade inflammation (IL‑6, TNF‑α, hs‑CRP ↓ ≈ 15 – 25 %) and nudges T‑cell immunity toward a less‑senescent phenotype. Effects are robust for cytokines and modest—but directionally favourable—for T‑cell subsets, offering a scalable, low‑risk adjunct to pharmacological anti‑inflammatories and potentially improving vaccine responsiveness.